Edition:
United States

AxoGen Inc (AXGN.OQ)

AXGN.OQ on NASDAQ Stock Exchange Capital Market

39.95USD
26 Apr 2018
Change (% chg)

$1.00 (+2.57%)
Prev Close
$38.95
Open
$39.05
Day's High
$40.90
Day's Low
$38.75
Volume
69,251
Avg. Vol
81,953
52-wk High
$41.70
52-wk Low
$11.65

Chart for

About

AxoGen, Inc. offers surgical solutions for peripheral nerve injuries. The Company provides products and education to improve surgical treatment algorithms for peripheral nerve injuries. Its portfolio of products includes Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector and Avive Soft Tissue Membrane. Along... (more)

Overall

Beta: -0.04
Market Cap(Mil.): $1,337.48
Shares Outstanding(Mil.): 34.56
Dividend: --
Yield (%): --

Financials

  AXGN.OQ Industry Sector
P/E (TTM): -- 31.31 32.21
EPS (TTM): -0.31 -- --
ROI: -25.97 9.57 13.05
ROE: -52.09 13.99 14.90

BRIEF-Axogen Inc Q4 Adjusted Loss Per Share $0.07

* AXOGEN, INC. REPORTS 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Feb 28 2018

BRIEF-Axogen Sees Q4 Revenue At Least $16.5 Million

* FY2017 REVENUE VIEW $59.2 MILLION -- THOMSON REUTERS I/B/E/S

Jan 08 2018

BRIEF-Axogen Announces Avance Nerve Graft Recipient Selected To Ride On Donate Life Rose Parade Float

* AXOGEN CORPORATION ANNOUNCES AVANCE® NERVE GRAFT RECIPIENT SELECTED TO RIDE ON DONATE LIFE ROSE PARADE® FLOAT Source text for Eikon: Further company coverage:

Dec 18 2017

BRIEF-Axogen, Inc. Announces pricing of public offering of common stock

* Axogen, Inc. Announces pricing of public offering of common stock

Nov 16 2017

BRIEF-Axogen announces proposed public offering of common stock

* Axogen Inc announces proposed public offering of common stock

Nov 15 2017

BRIEF-AxoGen reports Q3 loss per share $0.06

* Fy2017 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S

Nov 01 2017

Competitors

Earnings vs. Estimates